

Association between Blood N-3 Fatty Acid Levels and Risk for COVID-19 in the UK biobank

William S. Harris, PhD^{1,2}; Nathan L. Tintle, PhD^{1,3}, Swaminathan Perinkulam Sathyanarayanan, MD² and Jason Westra, MS¹

¹Fatty Acid Research Institute, Sioux Falls, SD, USA

²Department of Internal Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA.

³Department of Population Health Nursing Science, College of Nursing, University of Illinois – Chicago, Chicago, IL, USA

Sources of Support: This analysis was supported in part by the William H. Donner Foundation which played no role in any aspect of this investigation.

Conflict of Interest: WSH holds stock in OmegaQuant Analytics, LLC, a laboratory that offers blood fatty acid testing (including the Omega-3 Index) for researchers, clinicians and consumers.

Corresponding Author: William S. Harris, PhD. 5009 W. 12th St, Ste 5b, Sioux Falls, SD, 57106. (913) 302-9433; wsh@faresinst.com

Running Title: N-3 Fatty Acid Levels Predict COVID-19 Outcomes

Abbreviations: eO3I, estimated Omega-3 Index (erythrocyte EPA+DHA%)

Abstract

Background: The role of nutritional status and risk for contracting and/or suffering adverse outcomes from COVID-19 infection are unclear. Preliminary studies suggest that higher n-3 PUFA intakes may be protective. Objectives: The purpose of this study was to compare risk for three COVID-19 outcomes (testing positive, hospitalization, and death) as a function of baseline plasma DHA levels. Methods: DHA levels (% of total fatty acids) were measured by NMR. The three outcomes and relevant covariates were available for 110,688 subjects (hospitalization and death) and for 26,620 ever-tested subjects (positive COVID-19 PCR test result) via the UKBiobank prospective cohort study. Outcome data between January 1, 2020 and March 23, 2021 were included. Estimated Omega-3 Index (red blood cell EPA+DHA%) levels across DHA% quintiles were estimated. Multi-variable Cox-proportional hazards models were constructed and linear (per 1-SD) relations with risk for each outcome were computed. Results: In the fully adjusted models, subjects in quintile 5 of DHA% were 21% less likely to test positive than those in quintile 1 ($p<0.001$), and the risk for a positive test was 8% lower for each 1-SD increase in plasma DHA% ($p<0.001$). Quintile 5 subjects were also 27% less likely to be hospitalized than those in quintile 1 ($P<0.05$), and risk for hospitalization was 11% lower per 1-SD increase in DHA% ($p<0.001$). For death with COVID-19, risk was monotonically lower through quintile 4 ($p<0.05$ vs quintile 1), but in quintile 5, the risk reduction was partially attenuated and became non-significant. Estimated Omega-3 Index values across DHA quintiles ranged from 3.5% (quintile 1) to 8% (quintile 5). Conclusions: These findings suggest that nutritional strategies to increase circulating n-3 PUFA levels, such as increased consumption of oily fish and/or use of n-3 fatty acid supplements, may reduce risk for adverse COVID-19 outcomes.

Key Words: EPA, DHA, COVID-19, fish oil, epidemiology, observational, biomarker

Introduction

The COVID-19 pandemic has arguably been the most disruptive worldwide event since World War II. Its impact was felt not only in the health sector (morbidity and mortality), but also in the economic, social and political realms. A tremendous amount of research has been conducted on the causes of and treatments for the infection, including efforts to discover the factors that affect susceptibility to the disease. In addition to demographic and physiologic characteristics (e.g., obesity, age, underlying health conditions, socio-economic status, etc.), nutritional considerations have been explored. Nutrients such as zinc, vitamins C and D, as well as dietary bioactives (e.g., probiotics) have been suggested as possible protective agents against COVID-19 infection and/or severity(1). In addition to these, the long-chain n-3 fatty acids of marine origin – EPA and DHA - have also been proposed to be protective against COVID-19(2-5). DHA and EPA are the main precursors for inflammation resolving mediators, including maresins, resolvins and protectins (6). These mediators downregulate the production of cytokines and also improve macrophage-mediated removal of inflammatory debris, microbes and promote apoptosis of neutrophils(2). Accordingly, higher levels of EPA and DHA in the tissues could, in theory, reduce the severity of the inflammatory response to COVID-19 infection. Small (<100 patients) studies have reported that higher red blood cell levels of EPA+DHA (i.e., the Omega-3 Index, O3I(7)) at admission were associated with lower risk for adverse COVID-19 outcomes(8-10), and pilot intervention studies have reported possible benefits from n-3 supplementation(11-13). The availability of plasma DHA levels in a subset of individuals in the UK Biobank cohort(14) affords the opportunity to explore the relationships between n-3 biostatus and risk for COVID-19 outcomes. Two prior studies on this topic have been published. Julkunen et al.(15) and Sun et al.(16) both recently reported that higher DHA levels, among several other biomarkers, were associated with lower risk for infection with or hospitalization with COVID-19. The purpose of the present study was to expand upon the work of these investigators by 1) examining the n-3 relations with additional COVID-19 outcomes (i.e., death), 2) performing more granular analyses (i.e., quintiles), 3) exploring the effects of several covariates on these relationships, and 4) translating n-3 biostatus into the O3I, a more commonly used measure of n-3 status.

Methods

Participants: UK Biobank is a prospective, population-based cohort of approximately 500,000 individuals recruited between 2007 and 2010 at assessment centers across England, Wales and Scotland. Baseline data derived from questionnaires, biological samples and physical measurements were collected on all participating individuals, with longitudinal monitoring occurring via a mix of in-person and Electronic Medical Record data(14, 17). The participants completed a touchscreen questionnaire, which collected information on socio-demographic characteristics, diet, and lifestyle factors. Anthropometric measurements were taken using standardized procedures. The touchscreen questionnaire and other resources are shown on the UK Biobank website (<http://www.ukbiobank.ac.uk/resources/>). UK Biobank has ethical approval (Ref. 11/NW/0382) from the North West Multi-centre Research Ethics Committee as a Research Tissue Bank. This approval means that researchers do not require separate ethical clearance and can operate under the Tissue Bank approval. All participants gave electronic signed informed consent. The UK Biobank study was conducted according to the guidelines laid down in the

Declaration of Helsinki. The UK Biobank protocol is available online (<http://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf>).

A total of 117,946 individuals from the UKbiobank cohort had blood fatty acid data. We first, dropped people who died before January 1, 2020 (i.e., before the pandemic began), leaving a sample of N=111,240 individuals. After dropping a small number of individuals with missing covariates (listed below under Statistical methods) our final analysis dataset consisted of N=110,688.

Exposure: The primary exposure was plasma DHA (expressed as a percent of total plasma fatty acids) obtained from blood samples collected at time of enrollment using by NMR (Nightingale Health Plc, Helsinki, Finland(18)). In order to estimate the O3I associated with these DHA levels, we used an equation described by Schuchardt et al.(19), which found a correlation between the observed and estimated O3I of 0.83.

Outcomes: We examined three primary endpoints: (1) death from COVID, (2) hospitalization with confirmed COVID infection, and (3) having tested positive for COVID. Data were available on these three outcomes through March 23, 2021 including the outcome itself (yes/no) and the date for which the outcome was recorded. Any individuals recorded as having died and/or been hospitalized with COVID were imputed as having tested positive for COVID if not already noted as such in the dataset (N=174, 4% of the total). Because of inconsistencies in the reporting of testing data across regions of the UK (e.g., testing data was not available for Wales), and to provide a more precise outcome measure, the analysis sample for the ‘tested positive’ outcome, consisted of only individuals for whom a test result was available (e.g., ever tested; N=26,620).

Statistical Methods: Cox-proportional hazards models were used to predict all three outcomes. For each outcome, four separate models were run predicting the outcome using DHA% while using different sets of covariates with prior evidence of association with confirmed infection with COVID-19(20). Model 1 unadjusted; Model 2 adjusted for age at start of pandemic, sex, and race; Model included Model 2 covariates + waist circumference; and Model 4 included Model 3 covariates + Townsend Deprivation Index (a measure of relative socio-economic status), time since enrollment, smoking status, education, Self-reported health, blood pressure medications and slow walking pace. For models with sets of covariates which substantially attenuated hazard ratios (particularly Models 2 vs 3), the relative contribution of each individual variable to the explained variation was evaluated by a drop-one analyses. The effect of dropping each individual covariate illuminates the relative impact of each on the model concordances. Other covariates identified in prior studies(20) for test positivity included cystatin-C, HbA1c, forced expiratory volume, and HDL cholesterol. However, these variables were missing for ≈17% of subjects, thus, we only included them in a sensitivity analysis (Model 5 = Model 4 covariates + these four variables). As in prior studies, we focused primarily on modeling the relationships between DHA% and COVID outcomes with quintiles and continuous linear relationships. In secondary analyses we further investigated potential non-linearities using cubic splines. Cubic splines were compared to linear models using nested ANOVA to test for significant model improvement. All analyses were conducted in R version 4.1.2. and used a 0.05 statistical significance threshold.

Results

Descriptions of the analytic cohorts are presented in **Table 1**. Among the 110,688 people included in this study, the average age at the beginning of the pandemic was about 68, the vast majority were White and a little more than half were males. The average plasma DHA value was 2%, and the estimated Omega-3 Index (eO3I) was 5.6%. Less than 1% of the full cohort were hospitalized with COVID, and about 20% of them died from it. Among the 26,620 people in the dataset who ever got tested for COVID, about 15% tested positive at some point between January 1, 2020 and March 23, 2021. In those who got tested, plasma DHA% was similar to that of the whole cohort. When divided into quintiles, the plasma DHA% ranged from <1.48% in quintile 1 to >2.49% in quintile 5 (**Tables 2-4**). The median eO3I values corresponding to each plasma DHA% quintile ranged from 3.54% to 7.96% in quintiles 1 and 5, respectively (**Figure 1**).

Table 1. Distribution of analysis variables¹

	All	Ever tested for COVID
N	110,688	26,620
Sex - Male	61,000 (55.1%)	14,239 (53.5%)
Race - White	104,444 (94.4%)	25,061 (94.1%)
Positive tests ²	4084 (3.7%)	4084 (15.3%)
Hospitalized with COVID ²	838 (0.8%)	838 (3.1%)
Dead with COVID ²	235 (0.2%)	235 (0.9%)
Age (on January 1, 2020)	68.1 (8.1)	68.6 (8.2)
Years since enrollment	11.4 (0.9)	11.4 (0.9)
Estimated ³ Omega-3 Index (%)	5.6 (1.9)	5.6 (1.9)
Plasma DHA (% of total fatty acids)	2.0 (0.7)	2.0 (0.7)
Waist Circumference (cm)	90.0 (13.3)	91.2 (13.7)
BMI (kg/m ²)	27.4 (4.7)	27.8 (4.9)
Townsend Deprivation Index ⁴	-1.35 (3.08)	-1.17 (3.19)
Education - College/University	42106 (38.0%)	9657 (36.3%)
Smoking status - Never	61,236 (55.3%)	13,822 (51.9%)
Self-report health - Excellent	18606 (16.8%)	3946 (14.8%)
Long standing illness - None	74,205 (67%)	16,325 (61%)
Blood pressure medications - Yes	4844 (4.4%)	1398 (5.3%)
Diabetes - Yes	5339 (4.8%)	1629 (6.1%)
Walking pace – Slow ⁵	7943 (7.2%)	2483 (9.3%)

1. N (percent) or mean (SD)
2. Between January 1, 2020 and March 23, 2021
3. Based on Schuchardt et al. (cite)
4. An index of 0 means ‘average deprivation’ in the UK; a negative value means less deprived than average and a positive means more deprived than average.
5. <3 miles per hr (“steady” is 3-4 mph, and “fast” is >4 mph)

There was a strong, inverse and dose-related relationship between plasma DHA% and risk for having a positive COVID test (**Figure 1A**) which was partially attenuated with each level of multivariable adjustment (**Table 2**). Nevertheless, in the fully adjusted model, individuals in quintile 5 were 21% less likely to test positive than those in quintile 1 ($p<0.001$), and the risk for a positive test was 8% lower for each 1-SD increase in plasma DHA% ($p<0.001$).

As regards hospitalization with COVID, again there was again a significant, inverse association with the plasma DHA % which was partially attenuated with increasing adjustment (**Figure 1B**). In the fully adjusted model (**Table 3**), individuals in quintile 5 were at 27% lower risk for hospitalization than those in quintile 1 ($P<0.05$), and risk was 11% lower per 1-SD higher in DHA% ($p<0.001$).

Finally, for death from COVID, relations with plasma DHA% were more complex (**Figure 1C, Table 4**). In all models, risk for death was significantly lower in quintile 4 vs quintile 1 ($p<0.05$), but in quintile 5, the risk reduction was partially attenuated and not significant in three of the four models (the exception being model 2 where risk was 39% lower, $p<0.05$). In the unadjusted model and model 2, risk for death was 17% and 22%, respectively, lower ($p<0.05$) per 1-SD increase in DHA%. However, in the fully adjusted model, it was attenuated to non-significance (Table 4). Also in this model, the difference between risk for death in quintiles 4 and 5 was significant ($p=0.04$).

Table 2. Hazard ratios (HRs, 95% CI) by quintile for testing positive for COVID-19 as a function of plasma DHA% among those who were ever tested (n=26,620)

Plasma DHA% Quintile (min, max)	Unadjusted	Model 2 ¹	Model 3 ¹	Model 4 ¹
Q1 (<1.49; reference)	1	1	1	1
Q2 (1.49, 1.80)	0.94 (0.86,1.03)	0.96 (0.88,1.05)	0.99 (0.9,1.08)	1.00 (0.91,1.09)
Q3 (1.80, 2.10)	0.86 (0.78,0.94)**	0.90 (0.82,0.99)*	0.95 (0.86,1.04)	0.97 (0.89,1.07)
Q4 (2.10, 2.50)	0.73 (0.66,0.8)***	0.79 (0.72,0.87)***	0.85 (0.76,0.93)**	0.88 (0.8,0.98)*
Q5 (>2.50)	0.60 (0.55,0.67)***	0.68 (0.61,0.76)***	0.74 (0.67,0.82)***	0.79 (0.71,0.88)***
Linear across quintiles	0.89 (0.87,0.9)***	0.91 (0.89,0.93)***	0.94 (0.91,0.96)***	0.95 (0.92,0.97)***
Linear trend per SD	0.84 (0.81,0.86)***	0.87 (0.84,0.9)***	0.90 (0.87,0.93)***	0.92 (0.89,0.96)***

¹Model 2: adjusted for age at start of pandemic, sex, and race; Model 3: Model 2 covariates + waist circumference; Model 4: Model 3 covariates + Townsend Deprivation Index, time since enrollment, smoking status, education, Self-reported health, blood pressure medications and slow walking pace. * $p<0.05$; ** $p<0.01$; *** $p<0.001$.

Figure 1. The percent of individuals experiencing COVID-19 outcomes between January 1, 2020 and March 23, 2021 by quintile of the plasma DHA%. The median estimated Omega-3 Index of each quintile is also shown. A, testing positive; B, being hospitalized; and C, dying.




Table 3. Hazard ratios (HRs, 95% CI) for hospitalization with COVID-19 as a function of plasma DHA% (n=110,688)

Plasma DHA% Quintile (min, max)	Unadjusted	Model 2 ¹	Model 3 ¹	Model 4 ¹
Q1 (<1.49; reference)	1	1	1	1
Q2 (1.49, 1.80)	0.92 (0.76,1.11)	0.95 (0.79,1.15)	1.07 (0.88,1.29)	1.10 (0.91,1.33)
Q3 (1.80, 2.10)	0.72 (0.59,0.88)**	0.74 (0.61,0.91)**	0.90 (0.74,1.11)	0.96 (0.78,1.18)
Q4 (2.10, 2.50)	0.56 (0.45,0.69)***	0.56 (0.45,0.7)***	0.73 (0.59,0.92)**	0.81 (0.65,1.02)
Q5 (>2.50)	0.48 (0.38,0.6)***	0.46 (0.36,0.58)***	0.63 (0.5,0.8)***	0.73 (0.57,0.93)*
linear-trend-quintiles	0.82 (0.78,0.86)***	0.82 (0.78,0.86)***	0.89 (0.84,0.93)***	0.92 (0.87,0.97)**
linear-trend-per SD	0.75 (0.7,0.81)***	0.75 (0.69,0.81)***	0.84 (0.78,0.91)***	0.89 (0.82,0.96)**

Model 2: adjusted for age at start of pandemic, sex, and race; Model 3: Model 2 covariates + waist circumference; Model 4: Model 3 covariates + Townsend Deprivation Index, time since enrollment, smoking status, education, Self-reported health, blood pressure medications and slow walking pace. * p<0.05; ** p<0.01; *** p<0.001

Table 4. Hazard ratios (HRs, 95% CI) for death with COVID-19 as a function of plasma DHA% among those who lived to see the pandemic and were ever tested (n=110,688)

Plasma DHA% Quintile (min, max)	Unadjusted	Model 2 ¹	Model 3 ¹	Model 4 ¹
Q1 (<1.49; reference)	1	1	1	1
Q2 (1.49, 1.80)	0.84 (0.59,1.21)	0.86 (0.6,1.24)	0.97 (0.67,1.39)	1.02 (0.71,1.47)
Q3 (1.80, 2.10)	0.69 (0.47,1.01)	0.69 (0.47,1.01)	0.84 (0.57,1.24)	0.91 (0.62,1.35)
Q4 (2.10, 2.50)	0.42 (0.27,0.66)***	0.40 (0.25,0.63)***	0.53 (0.33,0.83)**	0.60 (0.38,0.95)*
Q5 (>2.50)	0.72 (0.49,1.05)	0.61 (0.41,0.9)*	0.85 (0.57,1.27)	1.01 (0.67,1.51)
linear-trend-quintiles	0.87 (0.8,0.96)**	0.84 (0.77,0.92)***	0.92 (0.83,1.01)	0.96 (0.87,1.05)
linear-trend-per SD	0.83 (0.72,0.95)**	0.78 (0.68,0.9)***	0.88 (0.77,1.01)	0.94 (0.82,1.08)

¹Model 2: adjusted for age at start of pandemic, sex, and race; Model 3: Model 2 covariates + waist circumference; Model 4: Model 3 covariates + Townsend Deprivation Index, time since enrollment, smoking status, education, Self-reported health, blood pressure medications and slow walking pace. * p<0.05; ** p<0.01; *** p<0.001

As mentioned for all three outcomes, there was some attenuation of the relationship between DHA% and risk with adjustment for covariates. Most of the attenuation in risk, particular for hospitalization and death, was seen in model 3 (age, sex, race and waist circumference). There was little additional attenuation when the other seven variables were included in model 4. It was therefore of interest to examine each of these four covariates to see the extent to which each was responsible the observed attenuation in relationship. This was done by computing the concordance between DHA% and each of the three outcomes, and then systematically removing each of the variables from the model and calculating the resultant drop in concordance. The results of this exercise are shown in **Table 5**. Regardless of the outcome, the removal of sex and then race from the covariate list had little effect on

the concordance. Age and waist circumference were the more important covariates. For testing positive, the inclusion of age had the greatest impact on the observed association with DHA%, decreasing the concordance by 45%. Comparatively, the removal of waist circumference reduced the concordance by only 3%. For hospitalization, waist circumference was the more influential, reducing concordance by 19% compared to 10% for age. For death, age was again the major factor followed by waist circumference, reducing the concordances by 32% and 8%, respectively.

Table 5. Effects of the removal of age, sex, race and waist circumference from model 3 on model concordance for the COVID-19 outcomes of interest.

	Concordance	Absolute Decrease				Percent Decrease*			
		Age	Sex	Waist circumference	Race	Age	Sex	Waist circumference	Race
Positive test	0.6298	0.0584	0.0001	0.0038	0.0042	45.0%	0.0%	3.0%	3.0%
Hospitalization	0.7047	0.0213	0.0011	0.0379	0.0121	10.0%	1.0%	19.0%	6.0%
Death	0.8088	0.0998	0.0011	0.024	0.0181	32.0%	0.0%	8.0%	6.0%

* Calculated by dividing the absolute decrease by the concordance - 0.5

As a sensitivity analysis we included a fifth model with diminished sample sizes (owing to missing covariate data, **Supplementary Table S1**) that additionally adjusted for cystatin-C, HbA1c, forced expiratory volume, and HDL cholesterol. The inclusion of these variables (and the loss of 17% of the sample owing to missing data) resulted in further attenuation of the DHA% vs. outcome relationships (**Supplementary Tables S2-S4**). Finally, secondary analyses using spline models did not significantly improve upon the continuous models for any outcome and for any level of adjustment (data not shown).

As noted, there were monotonic inverse relations between DHA% and risk for testing positive and for hospitalization. This was also true for death through the fourth quintile, but the trend reversed for the highest quintile. Thus, it was of interest to explore the differences in risk factor and demographic profiles across the quintiles of DHA% among the 235 individuals who died to see if some characteristic of those in quintile 5 might help explain this reversal, especially vs quintile 4 (where the favorable trend was still evident, **Supplementary Table S5**). The most obvious (and only statistically significant) difference between quintiles 5 and 4 was in reported fish oil supplement use, with 22% of the former reporting use and 61% of the latter ($p=0.002$). This naturally explains why this group had the highest DHA levels. Quintile 5 subjects were also less likely than to be white quintile 4 subjects (74% vs 93%, $p=0.1$).

Discussion

The purpose of this study was to examine the relationships between plasma DHA% at baseline in the UKBB and three COVID-19 related outcomes. We found that a 1-SD higher n-3 level was associated with an 8% lower risk for testing positive for COVID-19 and an 11% lower risk for hospitalization in the multivariable adjusted models. The relationship with risk for death was also lower (6% lower per 1-SD of DHA%), but it was not statistically significant. Thus, a higher n-3 level appeared to be protective against both getting infected with the virus and with having a severe enough infection to require hospitalization. Regarding risk for death with COVID-19, across the first four DHA% quintiles, risk decreased in a strongly dose-related manner. However, in the highest DHA quintile, the trend reversed, and the difference (from quintile 1) was no longer significant. Beyond the quintile 5 enrichment in subjects reporting fish oil supplement use and in non-white participants, the reasons for this partial reversal are unclear; but caution should be used given the small number of deaths ($n=235$). Finally, we were able to translate DHA% quintiles into the more familiar Omega-3 Index, and we found that the highest risk (i.e., quintile 1) eO3I value was around 3.5%, whereas the lowest risk (quintile 5) value was around 8%. These values comport well with the O3I risk cut points [originally proposed in 2004 for death from cardiovascular disease (7)] of <4% (high risk) and >8% (low risk) and imply that these target levels apply to COVID-19 outcomes as well.

The partial hazard ratio attenuations seen when adjusting for age and waist circumference were of particular interest in this study. Since there is a direct association between age and DHA% (here $r=0.11$, $p<0.001$), in models adjusting only for age (not shown), hazard ratios for the DHA-COVID outcome relationship became even stronger. Similarly, in models adjusting only for waist circumference (which was inversely associated with DHA%, $r=-0.28$, $p<0.001$), the DHA-COVID outcome relationship weakened. When comparing the effects of adjustment for age and for waist circumference by examining the weakening of model concordance using drop one analyses, it was clear that the latter metric was particularly important for the hospitalization (a surrogate for severity of illness) whereas the former was the more impactful covariate for testing positive and for dying with the infection. Thus, our analysis suggests that waist circumference and age are particularly important confounding variables that should be included in studies of the DHA vs COVID-19 relationship. However, adjusting for these variables only partially attenuated the DHA-COVID relationships suggesting that other factors also played a role in this association beyond by age and body fatness.

In general, our findings support the previous work of Julkunen et al. who reported on the relations between risk for severe (i.e., hospitalization with) COVID-19 and multiple circulating biomarkers in the UK Biobank(15). They found that a 1 SD increase in DHA% was associated with about a 23% reduction in risk for hospitalization in an age- and sex-adjusted model (compared to 25% here in Model 2). They did not adjust for any other covariates, however, nor did they report on either test positivity or mortality. Sun et al.(16) also published on the relationships between multiple fatty acid metrics and COVID-19 outcomes in the UKBB. Our report also differs from theirs in several ways. First, we were able to translate NMR plasma FA data to the eO3I, a metric that has been widely used clinically to risk stratify patients for a variety of conditions(21-27). Second, although Sun et al. adjusted for more variables than Julkunen et al. did, their list included only age, sex, ethnicity, BMI, Townsend deprivation index, and

assessment center. As noted, we adjusted for additional variables including those reported by Ho et al.(20) to be significant determinants of risk for testing positive in hospital for COVID-19. Third, like Julkunen et al., Sun et al. did not examine risk for death. Finally, uniquely compared to others, we have reported quintile level relationships and explored non-linear relationships between DHA% and COVID-19 outcomes. The latter could help define optimal or target blood O3I levels potentially useful in clinical practice.

Outside of the UKBB, the associations between the O3I or other blood n-3 biomarkers and a variety of COVID-19 related outcomes in small studies (<100 patients each) were reported. We(8) and a research group in Chile(9, 10) have both shown that higher O3I levels were associated with better clinical outcomes. A study in 26 children with multi-system inflammatory syndrome linked to COVID-19 infection found lower levels of EPA and DHA compared with historical controls(28). Other reports from within the UKBB have described significant inverse relationships between reported fish oil supplement use (which is associated with a higher O3I(19) and risk for death from all causes, risk for incident cardiovascular events(29) as well as primary liver cancer(30), inflammatory bowel disease(31) and dementia(32).

A few double-blind, randomized, controlled trials (RCTs) have used n-3 PUFAs to treat COVID-19 infection. Doaei et al. compared an n-3 FA enriched enteral nutrition product (n=28) with regular enteral nutrition (n=73) critically ill patients hospitalized with COVID-19(13). The n-3 FA cohort had a higher 1-month survival rate (21% vs 3% p= 0.003), better renal function (serum creatinine 1.29 vs 1.68 p=0.02), arterial blood gas parameters (pH 7.3 vs 7.26 p=0.01, HCO₃ 22 vs 18.17 p=0.01). There was also a trend towards improved lymphocyte count in the study group (11.80 vs 11.59 p=0.05). Based on these findings, apart from having immune-modulating effects, n-3 FA supplementation may have beneficial effects on vascular endothelial function and microcirculation as evidenced by improvement in blood gas and renal function parameters. Sedhigiyani et al. compared hydroxychloroquine treatment to hydroxychloroquine plus n-3 FAs and found that patients randomized to the latter regimen had statistically significantly improved myalgias and fatigue, and lower erythrocyte sedimentation rates and CRP levels(33).

Ecological Considerations

South Korea and Japan have reported an extremely low severity of COVID-19 disease. Although masking practices, social distancing policies and other population-wide interventions no doubt contributed to this, it is interesting to note that the O3I values of healthy South Korean and Japanese individuals are about 8-12% and 7 – 11 % respectively, which is much higher compared to O3I of 4-5% in Western populations(34). A world-wide pattern linking higher n-3 FA intakes have lower rates of death with COVID-19 was documented by Vivar-Sierra et al(35) (Figure 2). Although only suggestive, this observation adds further support for a potential role of n-3 PUFAs in the prevention of fatal COVID-19 disease.




Figure 2. Relationship between the calculated intake of long chain n-3 FAs in six geographic regions and their reported case fatality rates from COVID-19 through December 2020. The number of countries included in each region were Eastern Mediterranean, 22; Africa, 46; Americas, 34; Europe, 51; Western Pacific, 22; and Southeast Asia, 11. Adapted from Vivar-Sierra, et al.(35)

Mechanisms

There are several mechanisms that could, in theory, explain the relationships observed here. Beginning with the reduced risk for positive infection, the SARS-COV-2 virus is known to infect the host cells via binding of the spike (S) glycoprotein with the surface ACE2 receptors, expressed in the pneumocytes and other cell types. A molecular study conducted by Toelzer, et al. showed that the omega-6 fatty acid linoleic acid binding to the S glycoprotein resulted in stabilization of the spiked protein in a locked conformation thus reducing the interaction with ACE2(36). An *in silico* study by Vivar-Sierra et al. found that DHA and EPA also had the potential to hold the S glycoprotein in a closed conformation, and that they appeared to be more effective than linoleic acid. These findings were confirmed by Goc et al.(37) who studied the effect of EPA and alpha linolenic (ALA, plant-derived n-3 FA) on host cellular proteases such as transmembrane protease serine protease-2 (TMPRSS-2) and cathepsins that cleave spike proteins and enable cellular entry. Both EPA and ALA effectively inhibited the enzymatic activity of cathepsin L and TMPRSS2. EPA showed higher efficacy than ALA, however (73 % vs 20%). Finally, n-3 PUFAs may also play a role in intracellular mechanisms of inhibiting viral replication. MERS-CoV is known to reprogram the Sterol Regulatory Element Binding Protein (SREBP) dependent lipogenesis pathway to ensure its replication(38). N-3 fatty acids are intracellular inhibitors of SREBP transcription and maturation and may play role in counteracting the viral activation of SREBP1/2 thus decreasing viral replication(5). If operative *in vivo*, such an effect of EPA and DHA on not only the conformation of the S glycoprotein but also intracellular processes could reduce the ability of the virus to be replicated and spread, leading potentially to a lower risk for a positive test.

N-3 fatty acids are known to have anti-inflammatory actions via alterations in membrane physiochemistry which alter the activity of toll-like receptor 4, diminishing signal transduction to nuclear factor kappa B which in turn blunts the signaling cascade that produces inflammatory cytokines and adhesion molecules(39). In addition, when n-3 fatty acids are released from cell membranes by activation of phospholipases, they serve as substrates for the production of a wide array of oxylipins (prostaglandins, leukotrienes, and inflammation resolving mediators) that work in harmony not only suppress inflammatory pathways, but also actively promote the resolution of inflammation (for reviews see (2-4, 40, 41)). Consistent with this is the observation that a low plasma n-3 FA level was associated with elevated plasma level of the proinflammatory cytokine interleukin-6 in COVID-19 patients(42), and a higher DHA plasma level was associated with better lung function (i.e., forced expiratory volumes) in an 11-study meta-analysis(43). Taken together, there is a strong scientific rationale for a favorable effect of higher tissue n-3 levels and protection against both infection with COVID-19 and its downstream sequelae.

Strengths and weakness

The greatest strength of this study was the ability to query the UKBB data base with >110,000 individuals with baseline n-3 FA levels measured and then followed for >10 years. Second, we were able to link blood n-3 levels with three important COVID-19 related outcomes: positive testing, hospitalization and death. We also considered several more relevant covariates in our modeling than past authors have included reducing the chances for – but by no means eliminating - unmeasured confounding. Finally, we translated NMR-derived n-3 metrics into the more familiar and clinically useful O3I metric.

As to limitations, the first is one common to of all studies linking circulating fatty acid levels measured at baseline with disease outcomes occurring many years later: how stable are blood n-3 FA levels over time? How confident can we be that levels measured at baseline were the same at the outbreak of the pandemic? Although blood was collected and plasma isolated and frozen at -80C between 2006-2009, it was not analyzed for FA composition until 2014-15. While stability of plasma samples stored at -80 for at least 12 years has been documented(44), within-person or biological stability has been less well-studied. We earlier showed that in the Framingham Offspring cohort, the within-person stability of the RBC-based O3I metric between 1999 and 2006 in subjects who did not initiate fish oil supplementation; in those who did, it increased by about 2%(45). Other studies have also examined plasma fatty acid stability over time. In the Cardiovascular Health Study, plasma phospholipid fatty acids were measured three times: at baseline and years 6 and 13(46). The correlation between the first and second sampling for DHA was 0.79 and the first and third sampling, 0.71. Ma et al. found correlations of 0.4-0.5 for within-person EPA and DHA levels measured three years apart in the Atherosclerosis Risk in Communities cohort(47), and similar repeatability was observed in both the EPIC-Norfolk study over 13 years(48) and in the Physician's Health Study over 15 years(49). Importantly, when baseline levels and follow-up levels were each used to predict risk for incident heart failure in the latter study, both metrics were equally predictive. Hence there is reasonable support for the use of baseline n-3 biomarker levels as predictors of incident disease. In the UKBB cohort, baseline fish oil supplement use was reported by 31% and the consumption of at least 2 meals per week of oily fish by 17% (JPS), and in a small subset of

UKBB participants assessed in follow up visits, 76% of fish oil supplement users at baseline still reported taking them 4-5 years later(50). Major shifts in these variables would have primarily served to bias our observations towards the null, suggesting that the relationships detected may in fact be stronger than they appear.

Another potential limitation is the impact of vaccination status on our findings. The study period covered by this report was from January 1, 2020 (herein defined as the beginning of the pandemic) to March 23, 2021. By the latter date, about 38% of the UK population had received at least one dose of the vaccine, but only 2.6% had received two doses(51). Could differential vaccination status have affected our findings? Vaccination has been shown to not only reduce the severity of COVID-19 once contracted, but also to lower the risk for testing positive(52). Unfortunately, data on vaccination status were not available for this analysis, but in order for differential vaccination status to have biased our results, one would have to posit that people with higher n-3 levels were more likely to have been vaccinated than those with lower levels during the approximately 3-4 month period of this study for which vaccines were available (Dec 2020-March 2021). Although this is plausible [i.e., higher n-3 levels are associated with higher SES and healthful behaviors and exercise and a greater consumption of oily fish and fish oil supplements(19)], we are unable to confirm or deny this hypothesis.

Finally, by its very nature, the UKBB is not a random selection of all individuals in the UK; it is limited to those in a fixed age range who agreed to participate. Thus, the results should not be generalized beyond that context, and outcome data (all taken from electronic medical records) were not formally adjudicated, potentially introducing some bias.

Conclusion

In this study we confirmed the findings of previous investigations that a low n-3 status was associated with increased risk for hospitalization with COVID-19. We extended these findings by also showing reduced risk for testing positive with the infection and by providing evidence that the risk for death may also be reduced. Furthermore, we identified eO3I levels associated with the least (<4%) and greatest (>8%) protection from COVID-19. Taken together, these results suggest that increased intakes of n-3 (from oily fish and/or taking n-3 supplements) should be encouraged to raise the O3I and possibly reduce the risk for COVID-19, and perhaps other, future pulmonary viral infections.

Acknowledgements

WSH designed the research; NLT conducted the research, analyzed the data and performed statistical analysis; JW assisted in variable and dataset creation; WSH, NLT and SPS wrote the paper; WSH had primary responsibility for the final content. All authors have read and approved the final manuscript.

Data Sharing

Codebook and analytic code related to data described in the manuscript will be made available upon reasonable request pending application to and approval by the Fatty Acid Research Institute. Raw data are available via standard application procedures directly from the UKbiobank.

References

1. Louca P, Murray B, Klaser K, Graham MS, Mazidi M, Leeming ER, et al. Modest effects of dietary supplements during the COVID-19 pandemic: insights from 445 850 users of the COVID-19 Symptom Study app. *BMJ Nutr Prev Health* 2021;4(1):149-57.
2. Panigrahy D, Gilligan MM, Huang S, Gartung A, Cortés-Puch I, Sime PJ, et al. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19? *Cancer metastasis reviews* 2020;39(2):337-40.
3. Hathaway D, Pandav K, Patel M, Riva-Moscoso A, Singh BM, Patel A, et al. Omega 3 Fatty Acids and COVID-19: A Comprehensive Review. *Infect Chemother* 2020;52(4):478-95.
4. Regidor PA, Santos FG, Rizo JM, Egea FM. Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19. *Medical hypotheses* 2020;145:110340.
5. Weill P, Plissonneau C, Legrand P, Rioux V, Thibault R. May omega-3 fatty acid dietary supplementation help reduce severe complications in Covid-19 patients? *Biochimie* 2020;179:275-80.
6. Chiang N, Serhan CN. Specialized pro-resolving mediator network: an update on production and actions. *Essays Biochem* 2020;64(3):443-62.
7. Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? *Prev Med* 2004;39(1):212-20.
8. Asher A, Tintle NL, Myers M, Lockshon L, Bacareza H, Harris WS. Blood omega-3 fatty acids and death from COVID-19: A pilot study. *Prostaglandins, leukotrienes, and essential fatty acids* 2021;166:102250.
9. Ramírez-Santana M, Zapata Barra R, Ñunque González M, Müller JM, Vásquez JE, Ravera F, et al. Inverse Association between Omega-3 Index and Severity of COVID-19: A Case-Control Study. *International journal of environmental research and public health* 2022;19(11):6445.
10. Zapata B. R, Müller JM, Vásquez JE, Ravera F, Lago G, Cañón E, et al. Omega-3 Index and Clinical Outcomes of Severe COVID-19: Preliminary Results of a Cross-Sectional Study. *International journal of environmental research and public health* 2021;18(15):7722.
11. Suh W, Urits I, Viswanath O, Kaye AD, Patel H, Hall W, et al. Three Cases of COVID-19 Pneumonia That Responded to Icosapent Ethyl Supportive Treatment. *Am J Case Rep* 2020;21:e928422.
12. Berger AA, Sherburne R, Urits I, Patel H, Eskander J. Icosapent Ethyl - A Successful Treatment for Symptomatic COVID-19 Infection. *Cureus* 2020;12(9):e10211.
13. Doaei S, Gholami S, Rastgoo S, Gholamalizadeh M, Bourbour F, Bagheri SE, et al. The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial. *J Transl Med* 2021;19(1):128.
14. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS medicine* 2015;12(3):e1001779.
15. Julkunen H, Cichońska A, Slagboom PE, Würtz P, Nightingale Health UKBI. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. *eLife* 2021;10:e63033.
16. Sun Y, Chatterjee R, Ronanki A, Ye K. Circulating Polyunsaturated Fatty Acids and COVID-19: A Prospective Cohort Study and Mendelian Randomization Analysis. *Front Med (Lausanne)* 2022;9:923746.
17. Collins R. What makes UK Biobank special? *Lancet* 2012;379(9822):1173-4.

18. Wurtz P, Raiko JR, Magnussen CG, Soininen P, Kangas AJ, Tynkkynen T, et al. High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. *Eur Heart J* 2012;33(18):2307-16.
19. Schuchardt JP, Tintle NL, Westra J, Harris WS. Determinants of the Omega-3 Index in the UK Biobank. *British Journal of Nutrition* 2022;xxx:xxx-yyy.
20. Ho FK, Celis-Morales CA, Gray SR, Katikireddi SV, Niedzwiedz CL, Hastie C, et al. Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. *BMJ open* 2020;10(11):e040402.
21. Block RC, Harris WS, Reid KJ, Sands SA, Spertus JA. EPA and DHA in Blood Cell Membranes from Acute Coronary Syndrome Patients and Controls. *Atherosclerosis* 2007;197:821-8.
22. Ammann EM, Pottala JV, Robinson JG, Espeland MA, Harris WS. Erythrocyte omega-3 fatty acids are inversely associated with incident dementia: Secondary analyses of longitudinal data from the Women's Health Initiative Memory Study (WHIMS). *Prostaglandins, leukotrienes, and essential fatty acids* 2017;121:68-75.
23. Harris WS, Del Gobbo L, Tintle NL. The Omega-3 Index and relative risk for coronary heart disease mortality: Estimation from 10 cohort studies. *Atherosclerosis* 2017;262:51-4.
24. McBurney MI, Tintle NL, Vasan RS, Sala-Vila A, Harris WS. Using an erythrocyte fatty acid fingerprint to predict risk of all-cause mortality: the Framingham Offspring Cohort. *Am J Clin Nutr* 2021.
25. Dai XW, Zhang B, Wang P, Chen CG, Chen YM, Su YX. Erythrocyte membrane n-3 fatty acid levels and carotid atherosclerosis in Chinese men and women. *Atherosclerosis* 2014;232(1):79-85.
26. Filipovic MG, Aeschbacher S, Reiner MF, Stivala S, Gobbato S, Bonetti N, et al. Whole blood omega-3 fatty acid concentrations are inversely associated with blood pressure in young, healthy adults. *Journal of hypertension* 2018;36(7):1548-54.
27. Markhus MW, Skotheim S, Graff IE, Froyland L, Braarud HC, Stormark KM, et al. Low omega-3 index in pregnancy is a possible biological risk factor for postpartum depression. *PloS one* 2013;8(7):e67617.
28. Verduci E, Risé P, Di Profio E, Fiori L, Vizzuso S, Dilillo D, et al. Blood Fatty Acids Profile in MIS-C Children. *Metabolites* 2021;11(11).
29. Li Z-H, Zhong W-F, Liu S, Kraus VB, Zhang Y-J, Gao X, et al. Associations of habitual fish oil supplementation with cardiovascular outcomes and all cause mortality: evidence from a large population based cohort study. *BMJ (Clinical research ed)* 2020;368:m456.
30. Jiang W, Li FR, Yang HH, Chen GC, Hua YF. Relationship Between Fish Oil Use and Incidence of Primary Liver Cancer: Findings From a Population-Based Prospective Cohort Study. *Front Nutr* 2021;8:771984.
31. Huang X, Li Y, Zhuang P, Liu X, Zhang Y, Zhang P, et al. Habitual Fish Oil Supplementation and Risk of Incident Inflammatory Bowel Diseases: A Prospective Population-Based Study. *Front Nutr* 2022;9:905162.
32. Ma H, Zhou T, Li X, Heianza Y, Qi L. Use of fish oil supplements is differently related to incidence of all-cause and vascular dementia among people with the distinct APOE ϵ 4 dosage. *Clinical nutrition (Edinburgh, Scotland)* 2022;41(3):731-6.
33. Sedighyan M, Abdollahi H, Karimi E, Badeli M, Erfanian R, Raeesi S, et al. Omega-3 polyunsaturated fatty acids supplementation improve clinical symptoms in patients with Covid-19: A randomised clinical trial. *International journal of clinical practice* 2021;75(12):e14854.
34. Schuchardt JP, Cerrato M, Ceseri M, DeFina LF, Delgado GE, Gellert S, et al. Red blood cell fatty acid patterns from 7 countries: Focus on the Omega-3 index. *Prostaglandins, leukotrienes, and essential fatty acids* 2022;179:102418.

35. Vivar-Sierra A, Araiza-Macías MJ, Hernández-Contreras JP, Vergara-Castañeda A, Ramírez-Vélez G, Pinto-Almazán R, et al. In Silico Study of Polyunsaturated Fatty Acids as Potential SARS-CoV-2 Spike Protein Closed Conformation Stabilizers: Epidemiological and Computational Approaches. *Molecules* 2021;26(3).
36. Toelzer C, Gupta K, Yadav SKN, Borucu U, Davidson AD, Kavanagh Williamson M, et al. Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein. *Science (New York, NY)* 2020;370(6517):725-30.
37. Goc A, Niedzwiecki A, Rath M. Polyunsaturated ω -3 fatty acids inhibit ACE2-controlled SARS-CoV-2 binding and cellular entry. *Scientific reports* 2021;11(1):5207.
38. Yuan S, Chu H, Chan JF, Ye ZW, Wen L, Yan B, et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. *Nat Commun* 2019;10(1):120.
39. Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. *Biochemical Society transactions* 2017;45(5):1105-15.
40. Kothapalli KSD, Park HG, Brenna JT. Polyunsaturated fatty acid biosynthesis pathway and genetics. implications for interindividual variability in prothrombotic, inflammatory conditions such as COVID-19. *Prostaglandins, leukotrienes, and essential fatty acids* 2020;162:102183.
41. Arnardottir H, Pawelzik SC, Öhlund Wistbacka U, Artiach G, Hofmann R, Reinholdsson I, et al. Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the COVID-Omega-F Trial. *Frontiers in physiology* 2020;11:624657.
42. Sertoglu E, Yucel C, Balık AR, Taşçı C, Bilge S, Ertuğrul MS, et al. Evaluation of erythrocyte membrane fatty-acid compositions in association with interleukin-6 levels in patients with COVID-19. *Nutrition (Burbank, Los Angeles County, Calif)* 2022;96:111581.
43. Xu J, Gaddis NC, Bartz TM, Hou R, Manichaikul AW, Pankratz N, et al. Omega-3 Fatty Acids and Genome-Wide Interaction Analyses Reveal DPP10-Pulmonary Function Association. *Am J Respir Crit Care Med* 2019;199(5):631-42.
44. Zeleniuch-Jacquotte A, Chajes V, Van Kappel AL, Riboli E, Toniolo P. Reliability of fatty acid composition in human serum phospholipids. *Eur J Clin Nutr* 2000;54:367-72.
45. Harris WS, Pottala JV, Vasan RS, Larson MG, Robins SJ. Changes in erythrocyte membrane trans and marine fatty acids between 1999 and 2006 in older Americans. *The Journal of nutrition* 2012;142(7):1297-303.
46. Lai HT, de Oliveira Otto MC, Lemaitre RN, McKnight B, Song X, King IB, et al. Serial circulating omega 3 polyunsaturated fatty acids and healthy ageing among older adults in the Cardiovascular Health Study: prospective cohort study. *BMJ (Clinical research ed)* 2018;363:363:k4067.
47. Ma J, Folsom AR, Eckfeldt JH, Lewis L, Chambless LE. Short- and long-term repeatability of fatty acid composition of human plasma phospholipids and cholesterol esters. *Am J Clin Nutr* 1995;62:572-8.
48. Zheng JS, Imamura F, Sharp SJ, Koulman A, Griffin JL, Mulligan AA, et al. Changes in plasma phospholipid fatty acid profiles over 13 years and correlates of change: European Prospective Investigation into Cancer and Nutrition-Norfolk Study. *Am J Clin Nutr* 2019;109(6):1527-34.
49. Djousse L, Petrone AB, Weir NL, Hanson NQ, Glynn RJ, Tsai MY, et al. Repeated versus single measurement of plasma omega-3 fatty acids and risk of heart failure. *European journal of nutrition* 2014;53(6):1403-8.
50. Liu X, Zhuang P, Li Y, Wu F, Wan X, Zhang Y, et al. Association of fish oil supplementation with risk of incident dementia: A prospective study of 215,083 older adults. *Clinical nutrition (Edinburgh, Scotland)* 2022;41(3):589-98.
51. Richie H, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, Hasell J, et al. Causes of death. <https://ourworldindata.org/covid-vaccinations?country=GBR#citation>, 2020.

52. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. *Int J Infect Dis* 2022;114:252-60.

Supplemental tables

Table S1. Distribution of analysis variables for individuals with data on cystatin-C, HbA1c and FEV

	All	Ever tested for COVID by 3/23/21
N	92453	21967
Sex - Male	51190 (55.4%)	11816 (53.8%)
Race - White	87561 (94.7%)	20755 (94.5%)
Positive tests ¹	3349 (3.6%)	3349 (15.2%)
Hospitalized for COVID ¹	652 (0.7%)	652 (3%)
Dead from COVID ¹	187 (0.2%)	187 (0.9%)
Age on January 1, 2020	68 (8.1)	68.4 (8.2)
Time since enrollment (yr)	11.4 (0.87)	11.4 (0.88)
Estimated Omega-3 Index (%)	5.6 (1.89)	5.57 (1.9)
Plasma DHA (% of total fatty acids)	2.02 (0.67)	2 (0.68)
Waist Circumference (cm)	89.73 (13.18)	90.93 (13.59)
Body Mass Index (kg/m ²)	27.3 (4.66)	27.68 (4.84)
Townsend Deprivation Index ²	-1.4 (3.04)	-1.23 (3.15)
Education - College/University	35437 (38.3%)	8075 (36.8%)
Smoking status - Never	51596 (55.8%)	11592 (52.8%)
Self-report excellent health	16158 (17.5%)	3433 (15.6%)
Long standing illness - None	63274 (68.4%)	13867 (63.1%)
Blood pressure medications - Yes	3964 (4.3%)	1133 (5.2%)
Diabetes - Yes	4241 (4.6%)	1289 (5.9%)
Walking pace – Slow ³	6046 (6.5%)	1836 (8.4%)
HDL-Cholesterol (mmol/L)	1.31 (0.32)	1.3 (0.32)
Cystatin C (mg/L)	0.9 (0.15)	0.91 (0.17)
HbA1c (mmol/mol)	35.84 (6.36)	36.21 (6.99)
Forced Expiratory Volume (L)	2.83 (0.79)	2.8 (0.79)

Table S2. Testing positive for COVID-19 among those who ever tested in five models (n=21,967)

Prevalence	Unadjusted	Model 2	Model 3	Model 4	Model 5
18.1% (844/4666)	1	1	1	1	1
16.3% (723/4424)	0.9 (0.81,0.99)*	0.92 (0.83,1.01)	0.95 (0.86,1.05)	0.96 (0.87,1.06)	0.97 (0.88,1.07)
16.1% (698/4340)	0.87 (0.79,0.97)**	0.93 (0.84,1.03)	0.98 (0.88,1.08)	1 (0.9,1.11)	1.02 (0.92,1.13)
13.3% (558/4184)	0.72 (0.65,0.8)***	0.79 (0.71,0.88)***	0.85 (0.76,0.95)**	0.9 (0.8,1)	0.92 (0.82,1.03)
12.1% (526/4353)	0.64 (0.58,0.72)***	0.73 (0.65,0.82)***	0.8 (0.71,0.9)***	0.86 (0.76,0.96)**	0.88 (0.78,0.99)*
linear-trend-quintiles	0.9 (0.88,0.92)***	0.93 (0.9,0.95)***	0.95 (0.93,0.98)***	0.96 (0.94,0.99)**	0.97 (0.94,1)*
linear-trend-perSD	0.85 (0.82,0.88)***	0.9 (0.86,0.93)***	0.93 (0.89,0.96)***	0.95 (0.91,0.99)**	0.96 (0.92,1)*
spline vs. linear	0.17	0.26	0.3	0.38	0.36

Model 2 = Age, Sex, Race

Model 3 = Model 2+ Waist

Model 4 = Model 3+ TDI, time since FA, smoking status, education, Self-reported health, BP meds and slow pace

Model 5 = Model 4 + Cystatin C, HBA1C, FEV, HDL

Table S3. Hospitalization for COVID-19 in five models (n=92,453)

Prevalence	Unadjusted	Model 2	Model 3	Model 4	Model 5
1% (178/18491)	1	1	1	1	1
0.9% (160/18488)	0.9 (0.73,1.11)	0.93 (0.75,1.15)	1.03 (0.83,1.28)	1.08 (0.87,1.33)	1.13 (0.91,1.4)
0.7% (130/18493)	0.73 (0.58,0.91)**	0.75 (0.6,0.94)*	0.91 (0.72,1.14)	0.97 (0.77,1.22)	1.04 (0.82,1.31)
0.5% (93/18487)	0.52 (0.41,0.67)***	0.53 (0.41,0.69)***	0.68 (0.53,0.88)**	0.76 (0.59,0.98)*	0.82 (0.63,1.07)
0.5% (91/18494)	0.51 (0.4,0.66)***	0.49 (0.38,0.64)***	0.67 (0.51,0.87)**	0.77 (0.59,1.01)	0.86 (0.66,1.14)
linear-trend-quintiles	0.83 (0.78,0.88)***	0.82 (0.78,0.87)***	0.89 (0.84,0.94)***	0.92 (0.87,0.98)**	0.95 (0.89,1.01)
linear-trend-perSD	0.76 (0.7,0.83)***	0.75 (0.69,0.82)***	0.85 (0.78,0.92)***	0.89 (0.82,0.97)*	0.93 (0.85,1.01)
spline vs. linear	0.2	0.29	0.52	0.63	0.63

Model 2 = Age, Sex, Race

Model 3 = Model 2+ Waist

Model 4 = Model 3+ TDI, time since FA, smoking status, education, Self-reported health, BP meds and slow pace

Model 5 = Model 4 + Cystatin C, HBA1C, FEV, HDL

Table S4. Death from COVID-19 in five models (n=92,453)

Prevalence	Unadjusted	Model 2	Model 3	Model 4	Model 5
0.3% (52/18491)	1	1	1	1	1
0.2% (39/18488)	0.75 (0.49,1.13)	0.78 (0.51,1.18)	0.87 (0.57,1.31)	0.92 (0.6,1.39)	0.94 (0.62,1.44)
0.2% (36/18493)	0.69 (0.45,1.06)	0.7 (0.45,1.07)	0.85 (0.55,1.31)	0.93 (0.6,1.43)	0.94 (0.61,1.46)
0.1% (22/18487)	0.42 (0.26,0.69)***	0.41 (0.25,0.68)***	0.54 (0.32,0.89)*	0.62 (0.37,1.03)	0.64 (0.38,1.07)
0.2% (38/18494)	0.73 (0.48,1.11)	0.63 (0.41,0.98)*	0.89 (0.57,1.38)	1.06 (0.67,1.65)	1.1 (0.7,1.75)
linear-trend-quintiles	0.89 (0.8,0.98)*	0.86 (0.77,0.95)**	0.93 (0.84,1.04)	0.98 (0.88,1.09)	0.98 (0.88,1.1)
linear-trend-perSD	0.85 (0.73,0.99)*	0.81 (0.69,0.94)**	0.91 (0.78,1.06)	0.97 (0.83,1.12)	0.98 (0.84,1.14)
spline vs. linear	0.33	0.44	0.59	0.66	0.67

Model 2 = Age, Sex, Race

Model 3 = Model 2+ Waist

Model 4 = Model 3+ TDI, time since FA, smoking status, education, Self-reported health, BP meds and slow pace

Model 5 = Model 4 + Cystatin C, HBA1C, FEV, HDL

Table S5. Distribution of demographic and health variables by quintile of plasma DHA% for those who died with COVID-19 (n=235; ranked by p-value comparing Q4 with Q5)

		Q1	Q2	Q3	Q4	Q5	Q4 vs. Q5
N		64	54	44	27	46	P-value
Fish oil supplement use	%	12.5	31.5	31.8	22.2	60.9	0.002
White	%	89.1	92.6	86.4	92.6	73.9	0.100
HBA1C (mmol/mol)	mean	44.05	40.48	40.58	37.33	40.48	0.100
Cystatin C (mg/L)	mean	1.07	1.08	1	0.93	0.97	0.240
Exercise > 660 min/wk	%	18.8	18.5	20.5	37	21.7	0.250
Age -years	mean	61.72	63.33	63.28	64.47	62.66	0.280
Obese	%	51.60%	50.00%	47.70%	40.70%	26.10%	0.300
Male	%	67.20%	66.70%	54.50%	48.10%	63.00%	0.320
Townsend Deprivation Index	mean	0.2	0.2	0.9	-0.65	0.07	0.400
Stroke before pandemic	%	7.8	7.4	9.1	3.7	10.9	0.530
Daily Alcohol use	%	15.6	16.7	27.3	22.2	15.2	0.660
Long standing illness	%	56.3	59.3	63.6	33.3	41.3	0.670
Urban	%	93.8	92.6	100	85.2	91.3	0.670
Rate health poor	%	6.3	11.1	20.5	11.1	6.5	0.800
Waist circumference (cm)	mean	103.75	101	99.27	95.74	94.96	0.830
Forced expiratory volume (L)	mean	2.47	2.67	2.42	2.55	2.51	0.860
Slow walking pace	%	28.1	29.6	18.2	11.1	15.2	0.890
Diabetes	%	18.8	20.4	25	14.8	10.9	0.900
HDL-C (mmol/L)	mean	1.07	1.18	1.21	1.3	1.31	0.900
Rate health excellent	%	9.4	9.3	2.3	7.4	10.9	0.940
Dementia before pandemic	%	6.3	16.7	18.2	29.6	26.1	0.960
Eat oily fish >=2x/wk	%	7.8	18.5	22.7	29.6	30.4	1.000
Smoker	%	20.3	11.1	20.5	7.4	8.7	1.000
College degree	%	15.6	27.8	35.4	37	37	1.000
Blood pressure medications	%	4.7	7.4	9.1	3.7	6.5	1.000
MI before baseline	%	6.3	7.4	9.1	11.1	13	1.000
MI before pandemic	%	12.5	18.5	15.9	14.8	15.2	1.000
Stroke before baseline	%	4.7	3.7	2.3	0	2.2	1.000

Table S6. Data sources

Variable	Source documentation
Covariates	
Sex	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=31
Race	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=21000
Age (on January 1, 2020) ¹	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=34
Years since enrollment ²	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=53
Estimated Omega-3 Index (%)	Schuchardt et al. (2022)
Plasma DHA (% of total fatty acids)	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=23457
Waist Circumference	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=48
BMI (kg/m ²)	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=21001
Townsend Deprivation Index	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=189
Education - College/University	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=6138
Smoking status - Never	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=1249
Self-reported health - Excellent	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=2178
Long standing illness- None	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=2188
Cystatin C	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=30720
Vitamin D	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=30890
HBA1c	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=30750
FEV	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=3063
Omega6	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=23452
BP meds	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=6177
HDL-C	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=23406
Diabetes – yes	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=2443
Walking pace - Slow	https://biobank.ndph.ox.ac.uk/showcase/field.cgi?id=924
Outcomes	
Positive test ³	https://www.ukbiobank.ac.uk/enable-your-research/about-our-data/covid-19-data
Hosp due to COVID ³	https://www.ukbiobank.ac.uk/enable-your-research/about-our-data/covid-19-data
Dead from COVID ³	https://www.ukbiobank.ac.uk/enable-your-research/about-our-data/covid-19-data

1. Computed as the difference between month/year of birth and Jan 2020.
2. Computed as the difference between enrollment date and Jan 1, 2020.
3. Data for this project was available via the emergency use COVID-19 research data portal available to UKBiobank researchers through the end of 2021. Continuing data is available via standard UKBiobank data access portals.